{
    "organizations": [],
    "uuid": "4fecc86bcf4859d415ad5bbbfda8ec6ddbbc8b1d",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/28/globe-newswire-argos-therapeutics-to-report-fourth-quarter-and-year-end-2017-financial-results-and-operational-highlights-on-monday-april.html",
    "ord_in_thread": 0,
    "title": "Argos Therapeutics to Report Fourth Quarter and Year-End Financial and Operational Highlights on Monday, April 2, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it will report fourth quarter and year-end 2017 financial results and operational highlights prior to the market open on Monday, April 2, 2018.\nAbout Argos Therapeutics\nArgos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.\nInvestor Contact:\nRichard Katz, MD, MBA\nArgos Therapeutics, Inc.\n919-287-6315\nrkatz@argostherapeutics.com\nMedia Contact:\nAdam Daley\nBerry & Company Public Relations\n212.253.8881\nadaley@berrypr.com\nSource:Argos Therapeutics, Inc.",
    "published": "2018-03-29T01:00:00.000+03:00",
    "crawled": "2018-03-29T00:48:57.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "durham",
        "march",
        "globe",
        "newswire",
        "argo",
        "therapeutic",
        "nasdaq",
        "args",
        "company",
        "focused",
        "development",
        "commercialization",
        "individualized",
        "immunotherapy",
        "based",
        "precision",
        "immunotherapy",
        "technology",
        "platform",
        "today",
        "announced",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "operational",
        "highlight",
        "prior",
        "market",
        "open",
        "monday",
        "april",
        "argo",
        "therapeutic",
        "argo",
        "therapeutic",
        "company",
        "focused",
        "development",
        "commercialization",
        "individualized",
        "immunotherapy",
        "treatment",
        "cancer",
        "infectious",
        "disease",
        "using",
        "technology",
        "platform",
        "argo",
        "advanced",
        "product",
        "candidate",
        "evaluated",
        "pivotal",
        "adapt",
        "phase",
        "clinical",
        "trial",
        "treatment",
        "metastatic",
        "renal",
        "cell",
        "carcinoma",
        "mrcc",
        "argo",
        "also",
        "developing",
        "separate",
        "product",
        "candidate",
        "treatment",
        "human",
        "immunodeficiency",
        "virus",
        "hiv",
        "currently",
        "evaluated",
        "phase",
        "clinical",
        "trial",
        "aimed",
        "hiv",
        "eradication",
        "adult",
        "patient",
        "funding",
        "development",
        "provided",
        "national",
        "institute",
        "health",
        "national",
        "institute",
        "allergy",
        "infectious",
        "disease",
        "collaboratory",
        "research",
        "aid",
        "eradication",
        "investor",
        "contact",
        "richard",
        "katz",
        "md",
        "mba",
        "argo",
        "therapeutic",
        "rkatz",
        "medium",
        "contact",
        "adam",
        "daley",
        "berry",
        "company",
        "public",
        "relation",
        "adaley",
        "source",
        "argo",
        "therapeutic",
        "inc"
    ]
}